US Psych Congress 2017

The 30th annual Psych Congress, hosted in New Orleans, Louisiana, from September 16-19, 2017, will bring together mental health professionals to discuss ways to improve patient outcomes through emerging research and cutting-edge psychiatric therapies. The Congress' focus on psychopharmacology, psychotherapy, and wellness offers valuable insights for mental health practitioners and other clinicians looking to continue their education. Sign up for our daily e-mail blasts on our registration page, and check back here during the conference for the full coverage.

Coverage

Dr Leslie Citrome on Coverage of Metabolic-Friendly Antipsychotics
   |    US Psych Congress 2017
Leslie Citrome, MD, MPH, of New York Medical College, discusses payer coverage of atypical antipsychotics with fewer metabolic side effects.
Dr Arwen Podesta: Better Communication and More Compassion Needed for Patients With Pain
   |    US Psych Congress 2017
There is a stigma that comes with being addicted to opioids, even if they are prescribed to manage pain, that can hurt the care patients need to receive, said Arwen Podesta, MD, ABPN, FASAM, ABIHM, of Tulane University.
Dr Thomas Kosten Highlights Payer Oversight of Opioids
   |    US Psych Congress 2017
Payers have made tremendous progress in improving oversight of opioids and other pain medications, but what is really needed is a shift to abuse-deterrent formulations, which are more expensive, said Thomas Kosten, MD, a psychiatrist with Baylor College of Medicine.
   |    US Psych Congress 2017 > Mary Caffrey
A survey of patients with ADHD showed that two-thirds of those who augment their morning medication do so because it stops working, and 42% have to plan their day around their medication fading.
   |    US Psych Congress 2017 > Mary Caffrey
Experts said that the frequency and quality of social relationships have a greater effect on mortality than obesity or drinking alcohol, and this commands attention from health systems.
Dr Kevin Hill: Policy Is Ahead of Science on Medical Cannabis
   |    US Psych Congress 2017
Right now, state policy regarding medical marijuana use is out ahead of the science, which can lead to predicaments where cannabis is prescribed in situations where it is not needed, explained Kevin P. Hill, MD, MHS, of Beth Israel Deaconess Medical Center and Harvard Medical School.
Dr Vladimir Maletic on the Challenge of Treating Major Depressive Disorder
   |    US Psych Congress 2017
Patients with childhood trauma may have reduced response to antidepressant agents, and physician need to be given more free rein to tailor treatment approaches to treat those with major depressive disorder, said Vladimir Maletic, MD, MS, clinical professor of neuropsychiatry and behavioral science at the University of South Carolina School of Medicine.
   |    US Psych Congress 2017 > Mary Caffrey
The debate over marijuana policy tends to be dominated by people with political "skin in the game," when what's needed is a balanced, evidenced-based review, said Kevin P. Hill, MD, MHS, of Beth Israel Deaconess Medical Center and Harvard Medical School.
Compendia
Adult ADHD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Hematology Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Pain Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST
Upcoming Partner Events
October 16-17, 2017
Washington, D.C.
October 24-25, 2017
San Francisco, CA
$vacMongoViewPlus$